<style type="text/css">body .wpex-vc-row-stretched, body .vc_row-o-full-height { visibility: visible; }</style> skip to Main Content

Investors Center

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.  Aramchol™ is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, in patients who are overweight or obese and pre-diabetes or type II diabetes mellitus.

Display Events
Chart Style
Back To Top